IDEXX实验室

IDEXX Laboratories Experiences MACD Death Cross, Bollinger Bands Narrowing

IDEXX Laboratories

Idexx Laboratories Crosses Below 200-Day Moving Average, Shares Down 4.9%

IDEXX Laboratories to Present at Institutional Investor Conferences

IDEXX Laboratories Exec VP Fennell George Buys 1,476 Shares, Sells 10,197 Shares

IDEXX Laboratories: KDJ Golden Cross, Bullish Marubozu Triggered on 15min Chart

Catalyst<ul> <li>Recent Bullish Engulfing and WR Oversold signals suggest potential upward momentum in IDXX.</li> <li>Most analysts rate IDXX Buy or Strong Buy, showing broad institutional optimism.</li> <li>Strong cash reserves relative to market value indicate solid financial health for IDXX.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state with no clear direction for IDXX.</li> <li>MACD Death Cross and MACD Golden Cross signals indicate conflicting market trends for IDXX.</li> <li>Medium and Extra-large fund flows show negative trends, suggesting reduced large investor confidence.</li></ul>

Key Factors

IDEXX Laboratories (IDXX) reported Q4 revenue growth of 14% reported and 12% organic, with capital instrument revenue up 76%.IDXX closed down 4.86% on February 12, 2026, despite beating EPS and revenue estimates and trading volume surged to $390 million.IDXX shares crossed below their 200-day moving average of $619.37, trading as low as $616.13 on February 13, 2026.IDXX is scheduled to present at the BofA Securities Animal Health Summit and the 47th Annual Raymond James Institutional Investors Conference in early 2026.For 2026, IDEXX provided organic revenue growth guidance of 7.0% to 9.0%, signaling a slowdown from prior growth rates.

IDXX News